Krystexxa Approved for Gout

For adults who can't use other therapies
By Scott Roberts
HealthDay Reporter

WEDNESDAY, Sept. 15 (HealthDay News) -- Krystexxa (pegloticase) has been approved by the U.S. Food and Drug Administration for adults with gout who do not respond to, or who cannot tolerate, standard treatments.

Krystexxa, given by injection every two weeks, metabolizes uric acid into a harmless byproduct that is excreted in the user's urine. The drug's safety and effectiveness were established in a pair of six-month clinical trials involving a total of 212 people.

The FDA warns that since severe allergic reactions were a common side effect of Krystexxa, a corticosteroid and antihistamine should be given beforehand to minimize this risk. Other common adverse reactions have included gout flares, nausea, bruising at the injection site, nasal irritation, constipation, chest pain and vomiting.

The agency said Krystexxa hadn't been evaluated in people with congestive heart failure, and should be dispensed to such users with caution.

The drug is produced by Savient Pharmaceuticals, based in East Brunswick, N.J.

More information

To learn more about gout, visit U.S. National Library of Medicine.

Copyright © 2010 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Debunking Three Rape Myths
Journal of Forensic Nursing, October/December 2014
Expires: 12/31/2016 CE:2.5 $24.95


Drug updates and approvals: 2014 in review
The Nurse Practitioner, 13December 2014
Expires: 12/31/2016 CE:3 $27.95


Can Food Processing Enhance Cancer Protection?
Nutrition Today, September/October 2014
Expires: 10/31/2016 CE:2 $21.95


More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events